

THE INNOVATION JOURNEY

Rethink Medical focuses on advanced urinary catheter technology (T Control), developed over a decade of R&D. Its device integrates a fluid control valve that addresses urinary tract infections while improving user autonomy. Rethink has already raised over €3.900.000, joined multiple accelerator programmes (CIMTI, EIT Health), and engaged with clinical validation partners. It showcases the capacity of ULPGC start ups to scale beyond regional boundaries with its global competitive medical technology.

Urinary Catheter Development

T-Control® urinary catheter is under regulatory clearance - Not available for commercial sale.



medical innovation . This dual value proposition directly aligns with global healthcare priorities focused on reducing hospital - acquired infections, lowe ring costs, and improving patients' quality of life — particularly in long - term care and home - use settings.

On a global scale, Rethink Medical's technology could disrupt a mature yet stagnant urinary care market by introducing a preventive, user - centered d esign that addresses unmet clinical needs. With effective regulatory approval strategies and targeted market entry — particularly in Europe and North America — the company could capture a meaningful share of the catheter device segment while setting new st andards for infection control and patient empowerment.

USEFUL LINKS

Reference:

<https://www.rethinkmedical.es>

THE INNOVATION IMPACT

Rethink Medical has the potential to make a significant impact on the global medical device market through its innovative approach to urinary catheter technology.

By integrating a fluid control valve that enhances both infection prevention and user aut onomy , Rethink Medical positions itself at the intersection of patient safety , clinical efficiency , and

